←
Sarrin Chethik71 posts
Sarrin Chethik avatar

Sarrin Chethik

@schethik

@UChi_MSA Views are my own

◷ Joined October 2015▧ 2 Photos and videos
Sarrin Chethik avatar
⟳ Sarrin Chethik retweeted
Sarrin Chethik@schethik·Jul 24

If you’re interested in how pull funding, prizes, or advance market commitments could work for drug repurposing, my colleagues and I have thought/written a lot more about the practical details. DM me and/or read more here: tinyurl.com/2w5c5vms.

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

Surely some of that dispersed knowledge exists in the famously guarded pharmaceutical industry (i.e., unpublished trial data, real-world evidence).

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

@JacobTref hits the nail on the head: “The cases where pull funding and prizes appeal more to me are when you have some reason to think that there is knowledge and data dispersed throughout different firms and the economy broadly.”

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

Funders could do the same. Funders like @coefficientgiving could continue directly funding the repurposing of generic drugs for NTDs, while they/others could also offer prizes for qualifying results that meet a sufficiently favorable cost-effectiveness threshold.

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

The Wild West provides an analogy. Sheriffs pursued the most promising leads themselves, but ALSO posted bounties to attract information and effort from outsiders. Bounties often only paid after a conviction (i.e., when they were successful). 🤠

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

Plus, the payout rules could be very simple. For example, only reward drug-disease combos that meet a cost-effectiveness threshold of $5,000 per DALY or better. That way, funders know in advance that they'll only pay for highly valuable outcomes.

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

While brilliant, there’s no way funders could push fund all the promising opportunities (there are tens of millions of drug-disease combinations and trials are expensive).

Sarrin Chethik avatar
Sarrin Chethik@schethik·Jul 24

Drug repurposing is having a moment. @US_FDA released an RFI, and @salonium/@JacobTref discuss ways to fix missing incentives, including push funding (paying upfront) + pull funding (paying based on outcomes). Jacob concludes, “Let’s do both.” That’s exactly the right attitude.

New episode of HARD DRUGS! Are miracle drugs hiding in plain sight? GLP-1 drugs have transformed diabetes and obesity, can help treat heart disease, kidney disease, sleep apnea, and may also work against dementia. But they’re far from the only medicine with more multiple uses. Aspirin, colchicine, minoxidil, Botox, and, famously, Viagra were all found to treat more conditions than expected. (Did you know that BCG vaccines are used to treat bladder cancer?) In fact, about a third of FDA-approved small molecule drugs are later approved for a second use. But sometimes, it takes several decades - and public funding - to learn whether existing drugs could work for more conditions. Moxidectin, for example, went untested for human diseases for decades; we now know that it can cure ~70% of whipworm infections in kids. Aspirin was used for over a century before we found it had cardiovascular benefits. Why? The commercial incentive to test further is time-limited: once a drug goes off-patent and generics can enter, drug developers can get undercut, so it’s no longer worth it to run expensive clinical trials to test other uses. The problem is even larger for tropical diseases, which are often not profitable to treat in the first place. The result is that we’re missing out on knowing about a lot of additional uses of already-approved drugs! There may be more miracle drugs hiding in plain sight. And economists estimate the ‘missing innovation’ would be worth 100 to 400 billion dollars in social value annually(!) How do we solve this? In this episode, @JacobTref and I chat about all the above and more!

2:31:43
Center for Global Development avatar
⟳ Sarrin Chethik retweeted
Center for Global Development@CGDev·Jun 25

Models suggest we could see ~3 COVID-scale pandemics this century. COVID showed that recovery slows and access suffers when vaccine manufacturing capacity is limited. Nearly a year after authorizations, only 9% of Africans were fully vaccinated. How do we avoid this bottleneck?